Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 72 of 79970 for:    subjects

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03042013
Recruitment Status : Withdrawn (Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.)
First Posted : February 3, 2017
Last Update Posted : July 11, 2017
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of the study is to evaluate long-term safety and tolerability of continuous treatment with ASP8273 in subjects who are participating in an Astellas-sponsored ASP8273 study which has completed, at a minimum, the primary analysis or have completed the individual study evaluation period and for whom the investigator feels the subject may have potential to continue to derive clinical benefit from treatment with ASP8273.

Condition or disease Intervention/treatment Phase
Subjects With NSCLC With an EGFR Activating Mutation Drug: ASP8273 Phase 2

Detailed Description:

This is a multicenter, rollover study for subjects with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) activating mutation who are currently participating in studies evaluating ASP8273.

Subjects should sign the informed consent at cycle 1 day 1 visit. The assessments from the last treatment visit from the parent study can be utilized for the cycle 1 day 1 visit. Either local or central laboratories may be utilized for the cycle 1 day 1 visit if assessments are used from the last treatment visit of the parent study. The subject will then receive ASP8273 study drug for the rollover study and return all ASP8273 study drug from the parent study. Subjects will continue on to subsequent 28-day cycles until 1 of the discontinuation criteria are met. Upon enrollment, subjects with fewer than 6 cycles of study drug dosing in the parent study will return to the clinic on day 1 of each cycle up to cycle 5. After cycle 5, these subjects can switch to day 1 of every other odd cycle for clinic visits. Subjects with 6 or more cycles of study drug dosing upon enrollment into the rollover study will return to the clinic on day 1 of every other odd cycle (e.g., cycles 3, 5, etc.). Imaging methods and frequency will be performed per standard of care.

An end of treatment study visit will be conducted 30 days after the last dose of study medication.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Rollover Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
Actual Study Start Date : February 28, 2017
Actual Primary Completion Date : February 28, 2017
Actual Study Completion Date : February 28, 2017

Arm Intervention/treatment
Experimental: ASP8273
Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
Drug: ASP8273
Oral




Primary Outcome Measures :
  1. Incidence of adverse events (safety and tolerability) [ Time Frame: Up to a maximum of 1 month (per cycle) ]
    An Adverse Event (AE) is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product

  2. Number of participants with laboratory value abnormalities and/or adverse events related to treatment [ Time Frame: Up to a maximum of 1 month (per cycle) ]
    Number of participants with potentially clinically significant laboratory values



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be participating in an Astellas-sponsored ASP8273 study which has completed, at a minimum, the primary analysis or have completed the individual study evaluation period requirements. Subject must not have met any discontinuation criteria in the parent study.
  • Subject must be receiving a stable dose of ASP8273 for 14 days minimum and is able to enroll into this rollover study without treatment interruption of study drug, or with no more than 21 consecutive days of treatment interruption in study drug within the parent study.
  • Subject should be deriving clinical benefit without any persistent intolerable toxicity from continued treatment of ASP8273.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

  • Subject who developed persistent intolerable toxicity to ASP8273 treatment in the parent study.
  • Subject who received any other systemic anticancer treatment after parent study entry (radiation to local areas such as bone or brain if received in the parent ASP8273 study is permitted).
  • Subject who requires the following medications will be excluded:

    • Chemotherapy, radiotherapy, immunotherapy or other medications intended for antitumor activity
    • Investigational products or therapy other than ASP8273
    • Strong inhibitors or inducers of CYP3A4
    • Permeability-glycoprotein (P-gp) substrates with a narrow therapeutic index
  • Subject has any condition which may require treatment during the study and may make the subject unsuitable for study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03042013


Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
Layout table for investigator information
Study Director: Senior Medical Director Astellas Pharma Global Development, Inc.

Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT03042013     History of Changes
Other Study ID Numbers: 8273-CL-0201
2016-003183-39 ( EudraCT Number )
First Posted: February 3, 2017    Key Record Dates
Last Update Posted: July 11, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
ASP8273
Non-Small-Cell Lung Cancer
EGFR mutations
Oncology

Additional relevant MeSH terms:
Layout table for MeSH terms
Naquotinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action